Laurence Vanlemmens

3.5k total citations
70 papers, 961 citations indexed

About

Laurence Vanlemmens is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Laurence Vanlemmens has authored 70 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 23 papers in Cancer Research and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Laurence Vanlemmens's work include Cancer survivorship and care (23 papers), Cancer Treatment and Pharmacology (20 papers) and Breast Cancer Treatment Studies (19 papers). Laurence Vanlemmens is often cited by papers focused on Cancer survivorship and care (23 papers), Cancer Treatment and Pharmacology (20 papers) and Breast Cancer Treatment Studies (19 papers). Laurence Vanlemmens collaborates with scholars based in France, United States and Italy. Laurence Vanlemmens's co-authors include Joëlle Fournier, Jacques Bonneterre, Thierry Soussi, Richard Lubin, Véronique Christophe, Jean-­Marc Ferrero, Marla Jo Brickman, Kenneth A. Kern, Xavier Pivot and Hiroji Iwata and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Laurence Vanlemmens

63 papers receiving 940 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laurence Vanlemmens France 15 675 244 198 169 119 70 961
L. Phuong United States 19 502 0.7× 331 1.4× 186 0.9× 360 2.1× 135 1.1× 42 1.3k
Elaine Anderson United Kingdom 17 385 0.6× 332 1.4× 100 0.5× 119 0.7× 61 0.5× 32 1.0k
S. Jezdic Italy 9 316 0.5× 319 1.3× 233 1.2× 144 0.9× 110 0.9× 15 795
Roger Allison Australia 18 460 0.7× 101 0.4× 192 1.0× 120 0.7× 70 0.6× 28 1.1k
Michaela L. Tsai United States 17 561 0.8× 244 1.0× 200 1.0× 101 0.6× 56 0.5× 35 850
Uwe Güth Switzerland 22 694 1.0× 457 1.9× 178 0.9× 205 1.2× 139 1.2× 102 1.4k
Marianne Phillips Australia 14 461 0.7× 265 1.1× 157 0.8× 127 0.8× 236 2.0× 32 981
D. Serin France 15 759 1.1× 375 1.5× 127 0.6× 72 0.4× 203 1.7× 73 1.2k
Elisa Dama Italy 17 232 0.3× 299 1.2× 181 0.9× 306 1.8× 132 1.1× 33 840
N. Malamos Greece 15 649 1.0× 343 1.4× 212 1.1× 138 0.8× 38 0.3× 32 864

Countries citing papers authored by Laurence Vanlemmens

Since Specialization
Citations

This map shows the geographic impact of Laurence Vanlemmens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Vanlemmens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Vanlemmens more than expected).

Fields of papers citing papers by Laurence Vanlemmens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurence Vanlemmens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Vanlemmens. The network helps show where Laurence Vanlemmens may publish in the future.

Co-authorship network of co-authors of Laurence Vanlemmens

This figure shows the co-authorship network connecting the top 25 collaborators of Laurence Vanlemmens. A scholar is included among the top collaborators of Laurence Vanlemmens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurence Vanlemmens. Laurence Vanlemmens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meglio, Antonio Di, Julie Havas, Martina Pagliuca, et al.. (2024). Patterns of depressive symptoms among survivors of early-stage breast cancer (BC).. Journal of Clinical Oncology. 42(16_suppl). 12009–12009.
2.
Licaj, Idlir, Elodie Coquan, Tienhan Sandrine Dabakuyo‐Yonli, et al.. (2023). Baseline quality of life and chemotherapy toxicities in patients with early breast cancer. Cancer. 129(7). 1085–1095. 4 indexed citations
3.
Vaz-Luís, Inês, Antonio Di Meglio, Élise Martin, et al.. (2023). 2031O Randomized trial of a telephone-based weight loss intervention in overweight and obese patients (pts) with breast cancer (BC): The MEDEA trial. Annals of Oncology. 34. S1078–S1078.
4.
5.
Christophe, Véronique, et al.. (2022). Unmet supportive care needs of caregivers according to medical settings of cancer patients: a cross-sectional study. Supportive Care in Cancer. 30(11). 9411–9419. 11 indexed citations
6.
Havas, Julie, Daniele Presti, Davide Soldato, et al.. (2022). Abstract P3-12-12: ATTITUDE: Understanding and reducing ATTrition in longiTUDinal studiEs of cancer survivors. Cancer Research. 82(4_Supplement). P3–12. 1 indexed citations
7.
Vanlemmens, Laurence, Anne Congard, Aurélie Untas, et al.. (2022). Emotional processes in partners’ quality of life at various stages of breast cancer pathway: a longitudinal study. Quality of Life Research. 32(4). 1085–1094. 1 indexed citations
8.
Lervat, Cyril, et al.. (2020). Les soins de support pour améliorer l’accompagnement personnalisé des patients. Bulletin du Cancer. 108(2). 210–223. 3 indexed citations
9.
Heudel, Pierre-Étienne, Maryam Karimi, Cari Levy, et al.. (2020). 1710P International multicentric evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits (TV) during the COVID-19 outbreak. Annals of Oncology. 31. S1006–S1006. 1 indexed citations
10.
Vanlemmens, Laurence, et al.. (2019). Profiles of caregivers most at risk of having unmet supportive care needs: Recommendations for healthcare professionals in oncology. European Journal of Oncology Nursing. 43. 101669–101669. 25 indexed citations
11.
Portolan, Ghyslaine, Sophie Gautier, Laurence Vanlemmens, et al.. (2018). Pregnancy outcomes in women exposed to cancer chemotherapy. Pharmacoepidemiology and Drug Safety. 27(12). 1302–1308. 9 indexed citations
12.
Pistilli, Barbara, Angélo Paci, Stefan Michiels, et al.. (2018). Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort. Annals of Oncology. 29. viii704–viii704. 3 indexed citations
13.
14.
Sablin, Marie‐Paule, Delphine Loirat, Thomas Bachelot, et al.. (2017). Triple-NOTE (Triple Negative Outcome in ESME): Large recent real-world prognostic data on triple negative metastatic breast cancers (mTNBC).. Journal of Clinical Oncology. 35(15_suppl). e12592–e12592. 1 indexed citations
15.
Christophe, Véronique, et al.. (2015). The subjective experience of young women with non-metastatic breast cancer: the Young Women with Breast Cancer Inventory. Health and Quality of Life Outcomes. 13(1). 73–73. 13 indexed citations
16.
Kolesnikov-Gauthier, H., Laurence Vanlemmens, Marie‐Christine Baranzelli, et al.. (2011). Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG–PET after the first course. Breast Cancer Research and Treatment. 131(2). 517–525. 38 indexed citations
17.
Vanlemmens, Laurence, et al.. (1998). Age as a prognostic factor in breast cancer.. PubMed. 18(3B). 1891–6. 20 indexed citations
18.
Peyrat, Jean‐Philippe, et al.. (1998). Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.. PubMed. 4(1). 189–96. 20 indexed citations
19.
Adenis, Antoine, et al.. (1996). Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors.. PubMed. 16(4A). 2063–7. 2 indexed citations
20.
Hebbar, Mohamed, Jacques Bonneterre, Laurence Vanlemmens, et al.. (1995). Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancer.. PubMed. 5(4). 201–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Phuong Breakdown of academic impact, for papers by Elaine Anderson Breakdown of academic impact, for papers by S. Jezdic Breakdown of academic impact, for papers by Roger Allison Breakdown of academic impact, for papers by Michaela L. Tsai Breakdown of academic impact, for papers by Uwe Güth Breakdown of academic impact, for papers by Marianne Phillips Breakdown of academic impact, for papers by D. Serin Breakdown of academic impact, for papers by Elisa Dama Breakdown of academic impact, for papers by N. Malamos
Rankless by CCL
2026